Synsam AB (publ) (SYNSAM.ST)
SEK 44.4
(-1.99%)
SEK 44.4
(-1.99%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.02 Billion SEK | -34.12% |
| 2022 | 3.08 Billion SEK | 7.73% |
| 2021 | 2.85 Billion SEK | -55.49% |
| 2020 | 6.42 Billion SEK | -0.4% |
| 2019 | 6.44 Billion SEK | 7.06% |
| 2018 | 6.02 Billion SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.09 Billion SEK | -0.43% |
| 2024 Q1 | 2.5 Billion SEK | 3.6% |
| 2023 Q4 | 2.02 Billion SEK | -33.21% |
| 2023 Q2 | 3.1 Billion SEK | 0.55% |
| 2023 Q1 | 3.08 Billion SEK | 0.1% |
| 2023 Q3 | 3.03 Billion SEK | -2.0% |
| 2023 FY | 2.02 Billion SEK | -34.12% |
| 2022 Q4 | 3.08 Billion SEK | 0.82% |
| 2022 FY | 3.08 Billion SEK | 7.73% |
| 2022 Q3 | 3.05 Billion SEK | 0.43% |
| 2022 Q2 | 3.04 Billion SEK | 5.08% |
| 2022 Q1 | 2.89 Billion SEK | 1.26% |
| 2021 Q1 | 6.31 Billion SEK | -1.71% |
| 2021 Q4 | 2.85 Billion SEK | -51.1% |
| 2021 Q3 | 5.84 Billion SEK | -9.57% |
| 2021 Q2 | 6.46 Billion SEK | 2.41% |
| 2021 FY | 2.85 Billion SEK | -55.49% |
| 2020 FY | 6.42 Billion SEK | -0.4% |
| 2020 Q4 | 6.42 Billion SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | 6.44 Billion SEK | 7.06% |
| 2018 FY | 6.02 Billion SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AddLife AB (publ) | 2.53 Billion SEK | 20.087% |
| Biotage AB (publ) | 150 Million SEK | -1252.667% |
| Bonesupport Holding AB (publ) | 13.22 Million SEK | -15245.636% |
| Doxa AB (publ) | 3.6 Million SEK | -56261.111% |
| Elekta AB (publ) | 4.8 Billion SEK | 57.791% |
| iZafe Group AB (publ) | 279 Thousand SEK | -727140.143% |
| Ortivus AB (publ) | 3.57 Million SEK | -56671.125% |
| Ortivus AB (publ) | 3.57 Million SEK | -56671.125% |
| Q-linea AB (publ) | 12.9 Million SEK | -15622.588% |
| S2Medical AB (publ) | - SEK | -Infinity% |